CA2484583C - Procede d'etalonnage d'un dispositif de surveillance du glucose - Google Patents

Procede d'etalonnage d'un dispositif de surveillance du glucose Download PDF

Info

Publication number: CA2484583C
Authority: CA; Canada
Prior art keywords: calibration; glucose; glucose monitor; monitor data; interval
Prior art date: 1999-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002484583A

Other languages

English (en)

Other versions

CA2484583A1 (fr

Inventor

John J. Mastrototaro

Todd M. Gross

John Shin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medtronic Minimed Inc

Original Assignee

Medtronic Minimed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-25

Filing date

2000-02-24

Publication date

2007-09-18

2000-02-23 Priority claimed from US09/511,580 external-priority patent/US6424847B1/en

2000-02-24 Application filed by Medtronic Minimed Inc filed Critical Medtronic Minimed Inc

2000-08-31 Publication of CA2484583A1 publication Critical patent/CA2484583A1/fr

2007-09-18 Application granted granted Critical

2007-09-18 Publication of CA2484583C publication Critical patent/CA2484583C/fr

2020-02-24 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 351
239000008103 glucose Substances 0.000 title claims abstract description 351
238000000034 method Methods 0.000 title claims abstract description 70
239000008280 blood Substances 0.000 claims abstract description 99
210000004369 blood Anatomy 0.000 claims abstract description 99
238000012417 linear regression Methods 0.000 claims abstract description 36
238000004364 calculation method Methods 0.000 claims abstract description 29
230000005055 memory storage Effects 0.000 claims description 24
230000008569 process Effects 0.000 claims description 10
238000012935 Averaging Methods 0.000 claims description 7
238000005070 sampling Methods 0.000 claims description 7
238000012805 post-processing Methods 0.000 claims description 3
238000009534 blood test Methods 0.000 abstract description 2
230000035945 sensitivity Effects 0.000 description 45
230000000875 corresponding effect Effects 0.000 description 9
230000006641 stabilisation Effects 0.000 description 9
238000011105 stabilization Methods 0.000 description 9
230000008859 change Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
238000010586 diagram Methods 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 3
239000012530 fluid Substances 0.000 description 3
206010033675 panniculitis Diseases 0.000 description 3
210000004304 subcutaneous tissue Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
238000009434 installation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
239000010409 thin film Substances 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
238000010339 medical test Methods 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000010445 mica Substances 0.000 description 1
229910052618 mica group Inorganic materials 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000010363 phase shift Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
238000004513 sizing Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Landscapes

Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002484583A 1999-02-25 2000-02-24 Procede d'etalonnage d'un dispositif de surveillance du glucose Expired - Fee Related CA2484583C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12158499P	1999-02-25	1999-02-25
US60/121584		1999-02-25
US09/511580		2000-02-23
US09/511,580 US6424847B1 (en)	1999-02-25	2000-02-23	Glucose monitor calibration methods
CA002353486A CA2353486C (fr)	1999-02-25	2000-02-24	Procede d'etalonnage d'un dispositif de surveillance du glucose

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002353486A Division CA2353486C (fr)	1999-02-25	2000-02-24	Procede d'etalonnage d'un dispositif de surveillance du glucose

Publications (2)

Publication Number	Publication Date
CA2484583A1 CA2484583A1 (fr)	2000-08-31
CA2484583C true CA2484583C (fr)	2007-09-18

Family

ID=34068570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002484583A Expired - Fee Related CA2484583C (fr)	1999-02-25	2000-02-24	Procede d'etalonnage d'un dispositif de surveillance du glucose

Country Status (1)

Country	Link
CA (1)	CA2484583C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116718647A (zh) *	2023-06-09	2023-09-08	东北大学	一种气体传感器气敏性能适应方法
CN116725532A (zh) *	2023-06-30	2023-09-12	苏州合尔康医疗科技有限公司	一种全自动的bgm血糖校准cgm的方法及装置

2000
- 2000-02-24 CA CA002484583A patent/CA2484583C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2484583A1 (fr)	2000-08-31

Legal Events

Date	Code	Title	Description
2004-11-19	EEER	Examination request
2018-04-09	MKLA	Lapsed	Effective date: 20180226

Publication	Publication Date	Title
EP1154718B1 (fr)	2007-05-30	Procede d'etalonnage d'un dispositif de surveillance du glucose
US7029444B2 (en)	2006-04-18	Real time self-adjusting calibration algorithm
EP3517027B1 (fr)	2021-01-27	Système et procédé d'étalonnage d'un capteur de glucose
US7890295B2 (en)	2011-02-15	Real time self-adjusting calibration algorithm
EP2896357B1 (fr)	2020-06-03	Algorithme d'étalonnage de capteur modifié
EP1148808B1 (fr)	2011-09-21	Systeme de suivi medical de type holter a detecteur de substances a analyser
US20230181825A1 (en)	2023-06-15	Sensor data calibration based on weighted values
CA2484583C (fr)	2007-09-18	Procede d'etalonnage d'un dispositif de surveillance du glucose